FibroBiologics, Inc.
FBLG
$0.95
$0.022.00%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.12% | -23.90% | 5.14% | 8.89% | 10.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.85% | -30.23% | 50.30% | 39.27% | 31.33% |
| Operating Income | -11.85% | 30.23% | -50.30% | -39.27% | -31.33% |
| Income Before Tax | -0.68% | -4.68% | -1,055.60% | -618.71% | 41.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.68% | -4.68% | -1,055.60% | -618.71% | 41.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.68% | -4.68% | -1,055.60% | -618.71% | 41.30% |
| EBIT | -11.85% | 30.23% | -50.30% | -39.27% | -31.33% |
| EBITDA | -11.70% | 31.13% | -50.06% | -39.00% | -31.13% |
| EPS Basic | 51.07% | 40.64% | -799.17% | -539.24% | 52.54% |
| Normalized Basic EPS | 46.18% | 40.64% | -799.23% | -539.31% | 56.85% |
| EPS Diluted | 51.07% | 40.64% | -799.17% | -539.24% | 52.54% |
| Normalized Diluted EPS | 46.18% | 40.64% | -799.23% | -539.31% | 56.85% |
| Average Basic Shares Outstanding | 105.75% | 76.33% | 28.51% | 18.08% | -94.39% |
| Average Diluted Shares Outstanding | 105.75% | 76.33% | 28.51% | 18.08% | -94.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |